Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676061 · ClinicalTrials.gov registry record · Phase 4
Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™
A Phase 4 study, sponsored by Baylor Research Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT04676061 is a Phase 4 study that was terminated before completion, run by Baylor Research Institute. The registered enrollment target is 51 participants.
The verdict
NCT04676061, a Phase 4 study, was terminated before completion, sponsored by Baylor Research Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
Effects of norethindrone acetate (NTA) in patients with Nexplanon.
Interventions
- DRUG Placebo
- DRUG Norethindrone acetate (NTA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-02-11 |
| Est. Completion | 2023-03-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04676061
The ClinicalTrials.gov registry entry for NCT04676061 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04676061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04676061 about?
NCT04676061 is a clinical study titled "Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™". Effects of norethindrone acetate (NTA) in patients with Nexplanon.
What is the current status of trial NCT04676061?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2021-02-11. Estimated completion is 2023-03-10.
What interventions are being tested in trial NCT04676061?
The interventions under investigation include: Placebo (DRUG), Norethindrone acetate (NTA) (DRUG).
Who is sponsoring clinical trial NCT04676061?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.